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Detection of circulating tumour cells and micrometastases in
cancer patients could be useful in determining prognosis and in
monitoring systemic therapies (Hardingham et al, 1995; Diel et al,
1996; Pantel et al, 1996). Various techniques have been described
using conventional cytology, immunochemistry, polymerase chain
reaction (PCR) or reverse transcriptase-PCR (RT-PCR), but most of
them have limited sensitivity and/or specificity. PCR and RT-PCR
have been shown to be of great interest for the detection of chromo-
somal alteration specific of some haematological malignancies or
non-epithelial tumours. Methods, which have been developed for
the detection of epithelium-derived cancer cells are primarily based
on the amplification of tissue or lineage specific genes (Bostick
et al, 1998; Ghossein et al, 1998; Jung et al, 1999). Therefore, due
in part to the occurrence of circulating normal epithelial cells, they
fail to be specific for the detection of circulating carcinoma cell.
Telomerase, a specialized reverse trancriptase that adds telomeric
repeats at chromosome ends, is a potentially important biomarker
and prognostic indicator of cancer (Albanell et al, 1997; Engelhardt
et al, 1997). Absent from most of normal somatic cells, with the
exception of germ cells, stem cells and activated haematopoietic cells
(Hiyama et al, 1995), telomerase is expressed in most tumour cell
lines and in a majority of cancer. Reactivation of telomerase activity
by cancer cells appears to be an important step in tumorigenesis.
We aimed to assess the feasibility of the use of telomerase detec-
tion for the identification of circulating epithelial tumor cells in the
blood of cancer patients. Because of the normal expression of telom-
erase activity by activated lymphocytes (Broccoli et al, 1995; Hiyama
et al, 1995) in the blood, we developed a method that combines an
immunomagnetic isolation step allowing the separation of epithelial
cells from blood cells prior to perform the measurement of telomerase
activity by a telomeric repeat amplification protocol (TRAP)-ELISA.
This method has been previously applied to stage IV breast cancer
patients, showing that 21/25 of them were positive (Soria et al, 1999).
Detection of telomerase in circulating epithelial cells could thus
represent an important predictive tool to evaluate prognosis and to
monitor therapy in patients with cancer. Here, we demonstrate that
this technique is sensitive and specific and could be applied to other
carcinoma patients with metastatic lung and colon cancer.
MATERIALS AND METHODS
Isolation of circulating epithelial cells
Blood samples (10 ml) were collected in heparinized tubes from 15
patients with stage IIIB (n = 2) or IV (n = 13) non-small cell lung
cancer (NSCLC), ages 38 to 71, 11 patients with colon cancer (stage
C (n = 2) or D (n = 9), Dukes classification), ages 28 to 83, and 30
age-matched healthy volunteers. Blood samples were stored at
room temperature for a maximum of 2 hours before experiments.
Peripheral blood mononuclear cells (PBMC) were then separated by
Ficoll density gradient (Figure 1A). Briefly blood samples were
diluted in 3 volumes of RPMI, layered on 10 ml of Ficoll (Life
Technologies, Cergy Pontoise, France) and then centrifuged at 2200
rpm for 25 min at 20˚C. PBMC were then collected, washed 2 times
in RPMI, and then resuspended in 1 ml of PBS, 2% fetal calf serum
(FCS). Then, 12.5 ´ 106 prewashed immunomagnetic beads cova-
lently coated with the BerEP4 monoclonal antibody (DYNAL A.S.,
Oslo, Norway) were added (Figure 1B). The BerEP4 monoclonal
antibody recognizes an epitope on the protein moiety of two 34 and
39 kDa glycopeptides expressed at the surface of epithelial cells in
normal and malignant tissues (Latza et al, 1990). After 30 min at
4˚C, cells bound to the beads were harvested using a magnetic field
(Figure 1C). Harvested epithelial cells (HEC) were then washed 3
times with PBS, 2% FCS. Washing efficiency was systematically
controlled by microscopic examination (Figure 2). Immuno-
fluorescence staining performed on some selected samples using
monoclonal antibodies directed against lymphocyte determinants:
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lack of detectable contaminating lymphocytes among HEC fractions
(data not shown). HEC were incubated for 30 min at 4˚C in 100 ml
of lysis buffer (CHAPS) containing 150 U ml-1 RNasin (Promega,
Madison, WI, USA). After a centrifugation at 16 000 g for 20 min at
4˚C, supernatants were collected and stored at -80˚C until telo-
merase activity assay was performed. Protein concentrations were
determined using the Bio-Rad Protein Assay (Bio-Rad Laboratories,
California).
To evaluate the sensitivity and the specificity of the assay,
decreasing number of telomerase-positive cancer cells were added
to PBMC samples obtained from an healthy volunteer by serial
dilutions, and then submitted to immunomagnetic separation as
described previously. We used two human BerEP4-expressing
carcinoma cell lines: KB3.1, MCF-7 (Latza et al, 1990) and one
human BerEP4-negative leukaemia cell line: Kit 225 (kindly
provided by A Vazquez, INSERM U131, Clamart, France). We
have previously confirmed that KB3.1 and MCF7 cells express
BerEP4, although, mean number of immunomagnetic beads coated
on cells tended to indicate that KB3.1 cells express significantly
lower levels of BerEP4 than MCF7 do (data not shown).
Experiments were repeated at least twice for each cell line.
Telomeric repeat amplification protocol (TRAP)
Telomerase activity was measured twice in independent experi-
ments on 1 mg of proteins or on 20 ml of cell extracts when insuf-
ficient amounts of proteins were available. Furthermore, because
telomerase has an essential RNA component, aliquots of samples
were treated with RNase to assess the specificity of the reaction
(Kim et al, 1994). Assays were performed using TRAPeze ELISA
Telomerase detection kit (Oncor, Gaitherburg, MD) according to
manufacturer’s instructions. In brief, cell extracts were incubated
with biotinylated telomerase substrate oligonucleotide (b-TS) at
30˚C for 30 min. The extended products were amplified by a
polymerase chain reaction (PCR) using Taq polymerase
(Pharmacia Biotech, Uppsala, Sweden), the b-TS, RP primers and
a deoxynucleotide mix containing dCTP labeled with dinitro-
phenyl (DNP). The PCR conditions were 33 cycles of 94˚C for 30
s and 55˚C for 30 s on a PTC-200 thermocycler (M.J. Research,
Watertown, MA). The amplification products were immobilized
onto streptavidin-coated microtitre plates via biotin-streptavidin
interaction, and then detected by anti-DNP antibody conjugated
to horseradish peroxidase (HPR). After the addition of the perox-
idase substrate (3,3¢,5,5¢-tetramethylbenzidine or TMB), the
amount of TRAP products was determined by the measurement of
the absorbance at 450 nm and 690 nm.
Moreover, to confirm the ELISA results, amplified products
were systematically run on a 12.5% non-denaturing polyacry-
lamide gel electrophoresis (PAGE) in 0.5X TBE. Gels were
stained with SYBRgreen (dilution 1/10 000) and PCR amplifica-
tion products were visualized under UV light exposition.
Because samples could contain Taq polymerase inhibitors, an
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Figure 2 Circulating epithelial cells collected using BerEP4-coated
immunomagnetic beads from a stage IV NSCLC patient. Note the size of the
BerEP4-positive cells compared to the beads immunomagnetic beads (2.8 mm)
Healthy 
donors
Lung 
cancers
Colon 
cancers
Breast
cancers
n = 30 n = 15 n = 11 n = 25
(Soria et al, 1999)
0
0.5
1
1.5
T
e
l
o
m
e
r
a
s
e
 
a
c
t
i
v
i
t
y
 
(
O
D
)
2
2.5
Figure 3 Telomerase detection by TRAP-ELISA assay in HEC from lung,
colon and breast cancers (Soria et al, 1999). The cut-off of positivity was
fixed at 0.150, as recommended by the manufacturer and is represented by
the dotted line
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Figure 1 Method of detection of telomerase activity in circulating epithelial
cells. Blood samples are first subjected to Ficoll density gradient. Circulating
epithelial cells are then harvested from peripheral blood mononuclear cells
(PBMC) by immunomagnetic separation using BerEP4-coated beads. Finally,
telomerase activity is assayed on BerEP4 positive-circulating epithelial cellsinternal control band of 36 bp should be visible in all lanes on
PAGE.
RESULTS
Telomerase activity was never detected in the HEC fractions
collected from 30 healthy donors (Figure 3), whereas telomerase
was present in most of the corresponding BerEP4-negative
fractions (data not shown). This is consistent with previous data
showing that activated lymphocytes express telomerase (Broccoli
et al, 1995; Hiyama et al, 1995).
In order to develop a model system for the detection of rare
telomerase-positive epithelial cells in blood of cancer patients,
various numbers of cultured BerEP4-expressing carcinoma cells
(KB3.1 and MCF-7) were seeded into PBMC isolated from
a healthy donor. After immunomagnetic separation, we found
Telomerase activity in circulating carcinoma cells 633
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Figure 4 Sensitivity and specificity of telomerase detection in BerEP4-bearing cells harvested from PBMC. The figures (A) and (B) show the results of 
typical experiments in which KB31 (A) and MCF7 (B) were serially diluted in PBMC obtained from healthy donors and then submitted to immunomagnetic
separation using BerEP4-coated beads, as described in the Materials and Methods section. ELISA results (up) of telomerase activity assays were confirmed 
by a direct visualization of the TRAP ladder by PAGE and SYBRgreen staining (down). Bars indicate variations between two independent measurements of
telomerase activity. Lane 1: negative control (CHAPS); lane 2: HEC obtained from unseeded PBMC samples of the donor; lanes 3–8: 3000, 1000, 333, 111, 37,
and 12 KB3.1 (A) or MCF7 (B) cells, respectively, seeded per PBMC samples isolated from 10 ml of blood. (C) Same experiment using the BerEP4-negative
leukemia cell line KIT225. Lane 1: negative control (CHAPS); lane 2: KIT 225; lane 3: unseeded PBMC; lane 4: HEC obtained from unseeded PBMC; lane 5:
BerEP4-negative fraction after immunomagnetic separation perform on unseeded PBMC; lane 6: HEC obtained from PBMC samples seeded with 3000 KIT 225
cells; lane 7: BerEP4-negative fraction obtained from PBMC samples seeded with 3000 KIT 225 cellstelomerase activity in BerEP4-positive cell fractions, even when
only 12 carcinoma cells were added to PBMC samples isolated
from 10 ml of whole blood (Figure 4A and 4B).
No telomerase activity was detected in the HEC fractions when
the same experiment was performed with the BerEP4-negative
leukaemia cell line Kit 225 that express high levels of telomerase
activity (Figure 4C). Altogether, these results suggest that our
technique is sensitive and specific and allows the detection of rare
telomerase-positive BerEP4-bearing epithelial cells in blood of
cancer patients.
We thus applied this protocol to blood samples obtained from
cancer patients. We detected telomerase activity in HEC from
11/15 (73%) NSCLC patients and from 8/11 (72%) colon cancer
patients (Figure 3). Interestingly, the 2 patients with stage IIIB
NSCLC and also the 2 patients with stage C colon cancer were
telomerase-positive. RNase treatment of cell extracts prior to
telomerase assay completely eliminated the signals demonstrating
the specificity of the enzymatic detection. Furthermore, telo-
merase positive samples showed the characteristic processive
6-base pair ladder upon polyacrylamide gel electrophoresis (data
not shown).
DISCUSSION
Here we have demonstrated that our method allows the specific
and sensitive detection of circulating telomerase-positive epithe-
lial cells in the blood of carcinoma patients. The normal expres-
sion of telomerase by activated lymphocytes does not allow a
direct measure of telomerase activity in blood samples. To over-
come this problem, we used BerEP4-coated magnetic beads to
harvest epithelial cells from blood samples. In preliminary
experiments, we found that better results were obtained in doing
this purification step on PBMC isolated by Ficoll gradient
centrifugation. Microscope examination and immunofluores-
cence staining have shown the lack of detectable lymphocytes in
HEC samples obtained by this technique. The specificity of the
overall method was further confirmed by the lack of detectable
telomerase activity in HEC obtained from healthy donors, even
when cells from the highly telomerase-positive leukaemia cell
line KIT 225 were added to PBMC samples prior to immuno-
magnetic separation.
Experiments using two carcinoma cell lines revealed that our
method allows the detection of nearly 12 telomerase-positive
BerEP4-bearing cells/PBMC isolated from 10 ml whole blood.
Although levels of telomerase activity could differ considerably
between primary cancer cells and cultured cell lines, this result
shows that our method is adapted for the detection of extremely
rare circulating carcinoma cells.
Telomerase has been shown to be a marker of epithelial cancer
cells. We have previously detected telomerase activity in circu-
lating epithelial cells in 84% of metastatic breast cancer patients
(Soria et al, 1999). We have shown here that our method could be
successfully applied to other carcinomas such as colon and lung
cancers. Whereas normal colonic crypt epithelial cells exhibiting
stem cells properties express very weak telomerase activity within
the proliferative zone of the crypt (Tahara et al, 1995; Kolquist
et al, 1998), evidences have been accumulated over years to
suggest that telomerase is up-regulated as a function of increased
tumour cell invasion, tumour progression, and metastatic potential
in colon cancer (Engelhardt et al, 1997; Yoshida et al, 1999).
Similarly, at the tumour site, telomerase activity has been shown to
be an important prognostic factor for NSCLC (Albanell et al,
1997; Marchetti et al, 1999; Taga et al, 1999). Whereas we never
found telomerase activity in HEC samples from 30/30 healthy
donors, telomerase was expressed in more than 72% of the patients
with advanced carcinoma involved in this study. Including our
previous data concerning breast cancer patients (Soria et al, 1999),
we therefore found telomerase activity in HEC from 40/51 (78%)
patients with advanced cancer. Further studies, involving particu-
larly patients at different stages of the disease are now required to
determine the precise clinical and biological significance of telo-
merase expression or its lack in HEC. However the fact that we
found telomerase activity in HEC from 2/2 patients with stage IIIB
NSCLC and also 2/2 patients with stage C colon cancer highly
suggest that our method could be used at earlier stages of cancer
progression.
To conclude we have described here a simple and reliable
method based on telomerase activity assays that allows a specific
and sensitive detection of circulating carcinoma cells. Telomerase
detection on HEC may be more specific compared to other
described techniques involving epithelial specific genes (Bostick
et al, 1998; Ghossein et al, 1998; Jung et al, 1999) because it
allows a direct detection of a marker of epithelial tumour cells.
However, further studies should be performed to demonstrate the
value of this non-invasive method in determining diagnostic, pro-
gnostic and response to therapy.
ACKNOWLEDGEMENTS
The authors thank the nursing staff of the Service Gard in the
département de Médecine at Institut Gustave Roussy for their
helpful contributions.
REFERENCES
Albanell J, Lonardo F, Rusch V, Engelhardt M, Langenfeld J, Han W, Klimstra D,
Venkatraman E, Moore MA and Dmitrovsky E (1997) High telomerase activity
in primary lung cancers: association with increased cell proliferation rates and
advanced pathologic stage. J Natl Cancer Inst 89: 1609–1615
Bostick PJ, Chatterjee S, Chi DD, Huynh KT, Giuliano AE, Cote R and Hoon DS
(1998) Limitations of specific reverse-transcriptase polymerase chain reaction
markers in the detection of metastases in the lymph nodes and blood of breast
cancer patients. J Clin Oncol 16: 2632–2640
Broccoli D, Young JW and de Lange T (1995) Telomerase activity in normal and
malignant hematopoietic cells. Proc Natl Acad Sci USA 92: 9082–9086
Diel IJ, Kaufmann M, Costa SD, Holle R, von Minckwitz G, Solomayer EF, Kaul S
and Bastert G (1996) Micrometastatic breast cancer cells in bone marrow at
primary surgery: prognostic value in comparison with nodal status [see
comments]. J Natl Cancer Inst 88: 1652–1658
Engelhardt M, Drullinsky P, Guillem J and Moore MA (1997) Telomerase and
telomere length in the development and progression of premalignant lesions to
colorectal cancer. Clin Cancer Res 3: 1931–1941
Ghossein RA, Coit D, Brennan M, Zhang ZF, Wang Y, Bhattacharya S, Houghton A
and Rosai J (1998) Prognostic significance of peripheral blood and bone
marrow tyrosinase messenger RNA in malignant melanoma. Clin Cancer Res
4: 419–428
Hardingham JE, Kotasek D, Sage RE, Eaton MC, Pascoe VH and Dobrovic A
(1995) Detection of circulating tumor cells in colorectal cancer by
immunobead-PCR is a sensitive prognostic marker for relapse of disease.
Mol Med 1: 789–794
Hiyama K, Hirai Y, Kyoizumi S, Akiyama M, Hiyama E, Piatyszek MA, Shay JW,
Ishioka S and Yamakido M (1995) Activation of telomerase in human
lymphocytes and hematopoietic progenitor cells. J Immunol 155: 3711–3715
Jung R, Petersen K, Kruger W, Wolf M, Wagener C, Zander A and Neumaier M
(1999) Detection of micrometastasis by cytokeratin 20 RT-PCR is limited due
to stable background transcription in granulocytes. Br J Cancer 81: 870–873
634 LR Gauthier
British Journal of Cancer (2001) 84(5), 631–635 © 2001 Cancer Research CampaignKim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM,
Wright WE, Weinrich SL and Shay JW (1994) Specific association of human
telomerase activity with immortal cells and cancer [see comments]. Science
266: 2011–2015
Kolquist KA, Ellisen LW, Counter CM, Meyerson M, Tan LK, Weinberg RA, Haber
DA and Gerald WL (1998) Expression of TERT in early premalignant lesions
and a subset of cells in normal tissues [see comments]. Nat Genet 19: 182–186
Latza U, Niedobitek G, Schwarting R, Nekarda H and Stein H (1990) Ber-EP4: new
monoclonal antibody which distinguishes epithelia from mesothelial. J Clin
Pathol 43: 213–219
Marchetti A, Bertacca G, Buttitta F, Chella A, Quattrocolo G, Angeletti CA and
Bevilacqua G (1999) Telomerase activity as a prognostic indicator in stage I
non-small cell lung cancer. Clin Cancer Res 5: 2077–2081
Pantel K, Izbicki J, Passlick B, Angstwurm M, Haussinger K, Thetter O and
Riethmuller G (1996) Frequency and prognostic significance of isolated tumour
cells in bone marrow of patients with non-small-cell lung cancer without overt
metastases. Lancet 347: 649–653
Soria JC, Gauthier LR, Raymond E, Granotier C, Morat L, Armand JP, Boussin FD
and Sabatier L (1999) Molecular detection of telomerase-positive circulating
epithelial cells in metastatic breast cancer patients. Clin Cancer Res 5:
971–975
Taga S, Osaki T, Ohgami A, Imoto H and Yasumoto K (1999) Prognostic impact
of telomerase activity in non-small cell lung cancers. Ann Surg 230:
715–720
Tahara H, Kuniyasu H, Yokozaki H, Yasui W, Shay JW, Ide T and Tahara E (1995)
Telomerase activity in preneoplastic and neoplastic gastric and colorectal
lesions. Clin Cancer Res 1: 1245–1251
Yoshida R, Kiyozuka Y, Ichiyoshi H, Senzaki H, Takada H, Hioki K and Tsubura A
(1999) Change in telomerase activity during human colorectal carcinogenesis.
Anticancer Res 19: 2167–2172
Telomerase activity in circulating carcinoma cells 635
British Journal of Cancer (2001) 84(5), 631–635 © 2001 Cancer Research Campaign